You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)有份開發之新型肺炎疫苗獲美國FDA批准進行一期臨床試驗
阿思達克 11-03 17:50
遠大醫藥(00512.HK)公布,集團在腫瘤免疫領域及DNA技術研發平台的聯營公司OncoSec(ONCS.US),與Providence合作開發,針對新型冠狀病毒病的DNA疫苗CORVax12,獲得美國食品和藥物管理局(FDA)的新藥臨床試驗申請(IND)批准,並啟動研究者發起的一期臨床試驗。

集團指,該疫苗是目前唯一使用免疫刺激劑來促進對SARS-CoV-2病毒免疫反應的DNA疫苗,旨在作為預防性疫苗預防新型冠狀病毒病。Providence將組織開展CORVax12針對病毒的開放性一期臨床研究,以評估可編碼S蛋白的序列單獨使用或與IL-12聯合使用的安全性和免疫原性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account